What is Barrington Research’s Estimate for ANIK Q1 Earnings?

Anika Therapeutics, Inc. (NASDAQ:ANIK) – Investment analysts at Barrington Research issued their Q1 2026 earnings estimates for Anika Therapeutics in a research note issued on Thursday, March 13th. Barrington Research analyst M. Petusky anticipates that the biotechnology company will post earnings per share of ($0.16) for the quarter. Barrington Research has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for Anika Therapeutics’ current full-year earnings is ($0.84) per share. Barrington Research also issued estimates for Anika Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2027 earnings at ($0.45) EPS.

Separately, StockNews.com raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th.

Anika Therapeutics Trading Up 1.3 %

Anika Therapeutics stock opened at $16.11 on Monday. The company has a market cap of $235.95 million, a P/E ratio of -2.42 and a beta of 0.95. Anika Therapeutics has a 1-year low of $14.95 and a 1-year high of $29.12. The company has a fifty day simple moving average of $16.90 and a 200 day simple moving average of $19.40.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13). The business had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%.

Institutional Trading of Anika Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Connors Investor Services Inc. lifted its stake in Anika Therapeutics by 8.0% in the fourth quarter. Connors Investor Services Inc. now owns 11,560 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 861 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Anika Therapeutics by 9.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 980 shares during the last quarter. Wellington Management Group LLP lifted its stake in Anika Therapeutics by 3.7% in the fourth quarter. Wellington Management Group LLP now owns 39,785 shares of the biotechnology company’s stock valued at $655,000 after acquiring an additional 1,407 shares during the last quarter. HighTower Advisors LLC lifted its stake in Anika Therapeutics by 11.3% in the third quarter. HighTower Advisors LLC now owns 15,883 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 1,615 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Anika Therapeutics in the fourth quarter valued at $27,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.